Sanofi keeps foot on the gas, agree­ing to five-year col­lab­o­ra­tion with MD An­der­son

Just four months af­ter scor­ing its first can­cer drug ap­proval in a decade, Sanofi is stay­ing on the on­col­o­gy of­fen­sive.

The French phar­ma is plan­ning to ac­cel­er­ate the de­vel­op­ment of po­ten­tial treat­ments, part­ner­ing with the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter in a five-year col­lab­o­ra­tion. By com­bin­ing Sanofi’s pipeline with MD An­der­son’s top-notch clin­i­cal tri­al pro­gram in on­col­o­gy, the pair will launch bio­mark­er-dri­ven clin­i­cal stud­ies to bet­ter un­der­stand which drug cock­tails can ef­fec­tive­ly curb can­cer pro­gres­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.